Related Experiment Videos
Ropinirole in treatment-resistant depression: a 16-week pilot study
Paolo Cassano1, Lorenzo Lattanzi, Maurizio Fava
1Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA. pcassano@partners.org
Summary
Adjunctive ropinirole showed antidepressant efficacy in treatment-resistant depression (TRD). This pilot study found 40% of patients responded, with good tolerability, suggesting ropinirole as a potential augmentation strategy for TRD.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Treatment-resistant depression (TRD) poses a significant clinical challenge.
- Novel augmentation strategies are needed to improve treatment outcomes for TRD patients.
Purpose of the Study:
- To evaluate the antidepressant efficacy of adjunctive ropinirole in outpatients with TRD.
- To assess the tolerability and safety profile of ropinirole as an add-on therapy.
Main Methods:
- A pilot study involving patients diagnosed with major depressive episode and TRD.
- Ropinirole (0.25-1.5 mg/day) was added to existing antidepressant treatments (TCAs or SSRIs).
- Response defined by a ≥50% reduction in MADRS scores and Clinical Global Impression of Improvement.
Main Results:
- A significant decrease in Montgomery-Asberg Depression Rating Scale (MADRS) scores was observed (29.6 to 16.9, P < 0.02).
- 40% of patients (4 out of 10) met the criteria for treatment response.
- The most common adverse event was dizziness, leading to discontinuation in two patients.
Conclusions:
- Adjunctive ropinirole appears to be an effective augmentation strategy for selected TRD patients.
- Ropinirole demonstrated relatively good tolerability in this patient cohort.
- Further research is warranted to confirm these preliminary findings in larger studies.